Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 12/2008

01-12-2008 | Research Articles

A multicentre phase II study to evaluate sequential docetaxel followed by capecitabine treatment in anthracycline-pretreated HER-2-negative patients with metastatic breast cancer

Authors: Juan Bayo, María Lomas, Javier Salvador, Alberto Moreno, Manuel Ruiz, Alberto Rodríguez, José Fuentes, Ana Fernández-Freire, Reyes Bernabé, Andrea Fernández

Published in: Clinical and Translational Oncology | Issue 12/2008

Login to get access
Metadata
Title
A multicentre phase II study to evaluate sequential docetaxel followed by capecitabine treatment in anthracycline-pretreated HER-2-negative patients with metastatic breast cancer
Authors
Juan Bayo
María Lomas
Javier Salvador
Alberto Moreno
Manuel Ruiz
Alberto Rodríguez
José Fuentes
Ana Fernández-Freire
Reyes Bernabé
Andrea Fernández
Publication date
01-12-2008
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 12/2008
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-008-0295-5

Other articles of this Issue 12/2008

Clinical and Translational Oncology 12/2008 Go to the issue

Research Articles

Cost-effectiveness analysis of sunitinib in patients with metastatic and/or unresectable gastrointestinal stroma tumours (GIST) after progression or intolerance with imatinib

News and Views

Music therapy in oncology

Educational Series

“New” molecular taxonomy in breast cancer

Reviews

Human papillomavirus vaccine and cervical cancer prevention

Research Articles

Employment in a cohort of cancer patients in Spain. A predictive model of working outcomes

Educational Series

An update on the biology of cancer stem cells in breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits